Ryufin

Imerys

France · FR0000120859 · reports in EUR · Europe

The answers

From the annual report for the year to Dec 31, 2025. Each line says what it is based on.

Is it growing?To watch
Revenue −6.1% in the year to Dec 31, 2025, on the year before.
Is it a good business?To watch
It earned −16% on its shareholders' equity in the year to Dec 31, 2025.
Is it safe?Fair
Equity is 42% of its assets, and operations brought in cash in the year.
Is the price fair?n/a
Not answered: no exchange publishes this company's price for free reuse, so there is no P/E here.

The year

Year to Dec 31, 2025, consolidated, in EUR.

€3.4B

revenue

n/a

operating margin

−€409M

net profit

Year by year

As filed; an earlier year can differ from its own report when the company restated it.

Dec 2022Dec 2023Dec 2024Dec 2025
Revenue€4.3B€3.8B€3.6B€3.4B
Operating profit€318M€108Mn/an/a
Net profit to shareholders€237M€51M−€95M−€409M
Earnings per share€2.80€0.61−€1.12−€4.83
Dividend per share€1.55€3.85€1.35€1.45
Cash from operations€452M€603M€478M€428M
Capital spending€345M€330Mn/an/a
Cash€620M€585M€635M€470M
Total assets€7.9B€7.2B€6.7B€6.2B
Equity€3.4B€3.2B€3.3B€2.6B

What they do

In the company's own words, from the annual report.

Imerys offre des solutions fonctionnelles à haute valeur ajoutée pour un grand nombre de secteurs, depuis les industries de procédés jusqu’aux biens de consommation. Dans chacun de ses secteurs opérationnels, le Groupe mobilise sa connaissance des applications, son expertise technologique et sa maîtrise des sciences des matériaux pour proposer des solutions basées sur la valorisation de ses ressources minérales, des minéraux de synthèse et des formulations.

Source: the company’s annual financial report in ESEF, via filings.xbrl.org (XBRL International). Listed shares from ESMA’s FIRDS register; ESMA does not endorse this site. Ryufin computed the answers and ratios from the filed figures.